Hepatic Hippo signaling inhibits development of hepatocellular carcinoma
Primary liver cancer is one of the most common cancer worldwide. Hepatocellular carcinoma (HCC) in particular, is the second leading cause of cancer deaths in the world. The Hippo signaling pathway has emerged as a major oncosuppressive pathway that plays critical roles inhibiting hepatocyte prolife...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Association for the Study of the Liver
2020-10-01
|
| Series: | Clinical and Molecular Hepatology |
| Subjects: | |
| Online Access: | http://e-cmh.org/upload/pdf/cmh-2020-0178.pdf |
| _version_ | 1818302074083868672 |
|---|---|
| author | Yuchen Liu Xiaohui Wang Yingzi Yang |
| author_facet | Yuchen Liu Xiaohui Wang Yingzi Yang |
| author_sort | Yuchen Liu |
| collection | DOAJ |
| description | Primary liver cancer is one of the most common cancer worldwide. Hepatocellular carcinoma (HCC) in particular, is the second leading cause of cancer deaths in the world. The Hippo signaling pathway has emerged as a major oncosuppressive pathway that plays critical roles inhibiting hepatocyte proliferation, survival, and HCC formation. A key component of the Hippo pathway is the inhibition of yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ) transcription factors by the Hippo kinase cascade. Aberrant activation of YAP or TAZ has been found in several human cancers including HCC. It is also well established that YAP/TAZ activation in hepatocytes causes HCC in mouse models, indicating that YAP/TAZ are potential therapeutic targets for human liver cancer. In this review, we summarize the recent findings regarding the multifarious roles of Hippo/YAP/TAZ in HCC development, and focus on their cell autonomous roles in controlling hepatocyte proliferation, differentiation, survival and metabolism as well as their non-cell autonomous in shaping the tumor microenvironment. |
| first_indexed | 2024-12-13T05:33:07Z |
| format | Article |
| id | doaj.art-e8ef8c75c7a04c5795b45b9ca4c8be05 |
| institution | Directory Open Access Journal |
| issn | 2287-2728 2287-285X |
| language | English |
| last_indexed | 2024-12-13T05:33:07Z |
| publishDate | 2020-10-01 |
| publisher | Korean Association for the Study of the Liver |
| record_format | Article |
| series | Clinical and Molecular Hepatology |
| spelling | doaj.art-e8ef8c75c7a04c5795b45b9ca4c8be052022-12-21T23:58:01ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2020-10-0126474275010.3350/cmh.2020.01781546Hepatic Hippo signaling inhibits development of hepatocellular carcinomaYuchen Liu0Xiaohui Wang1Yingzi Yang2 Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA, USA Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA, USA Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA, USAPrimary liver cancer is one of the most common cancer worldwide. Hepatocellular carcinoma (HCC) in particular, is the second leading cause of cancer deaths in the world. The Hippo signaling pathway has emerged as a major oncosuppressive pathway that plays critical roles inhibiting hepatocyte proliferation, survival, and HCC formation. A key component of the Hippo pathway is the inhibition of yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ) transcription factors by the Hippo kinase cascade. Aberrant activation of YAP or TAZ has been found in several human cancers including HCC. It is also well established that YAP/TAZ activation in hepatocytes causes HCC in mouse models, indicating that YAP/TAZ are potential therapeutic targets for human liver cancer. In this review, we summarize the recent findings regarding the multifarious roles of Hippo/YAP/TAZ in HCC development, and focus on their cell autonomous roles in controlling hepatocyte proliferation, differentiation, survival and metabolism as well as their non-cell autonomous in shaping the tumor microenvironment.http://e-cmh.org/upload/pdf/cmh-2020-0178.pdfhippoyap/tazhepatocyteslivercarcinoma, hepatocellular |
| spellingShingle | Yuchen Liu Xiaohui Wang Yingzi Yang Hepatic Hippo signaling inhibits development of hepatocellular carcinoma Clinical and Molecular Hepatology hippo yap/taz hepatocytes liver carcinoma, hepatocellular |
| title | Hepatic Hippo signaling inhibits development of hepatocellular carcinoma |
| title_full | Hepatic Hippo signaling inhibits development of hepatocellular carcinoma |
| title_fullStr | Hepatic Hippo signaling inhibits development of hepatocellular carcinoma |
| title_full_unstemmed | Hepatic Hippo signaling inhibits development of hepatocellular carcinoma |
| title_short | Hepatic Hippo signaling inhibits development of hepatocellular carcinoma |
| title_sort | hepatic hippo signaling inhibits development of hepatocellular carcinoma |
| topic | hippo yap/taz hepatocytes liver carcinoma, hepatocellular |
| url | http://e-cmh.org/upload/pdf/cmh-2020-0178.pdf |
| work_keys_str_mv | AT yuchenliu hepatichipposignalinginhibitsdevelopmentofhepatocellularcarcinoma AT xiaohuiwang hepatichipposignalinginhibitsdevelopmentofhepatocellularcarcinoma AT yingziyang hepatichipposignalinginhibitsdevelopmentofhepatocellularcarcinoma |